Li Tao, PhD, discusses early US uptake of twice-yearly lenacapavir, faster prescription-to-injection timelines, and how ACA coverage milestones tracked with zero cost sharing and HIV diagnoses.
|Articles|November 4, 2022
Best of IDWeek 2022
Author(s)Nina Cosdon
Experts discuss a range of the most topical infectious disease research, presented at the recent IDWeek 2022 conference.
Advertisement
For the first time in 3 years, the IDWeek conference was held in-person.
Contagion was there, covering the latest developments in infectious disease research. Here's a roundup of some of our favorite interviews, featuring a range of the most significant topics covered at this year's conference.
What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.
After Helen Boucher, MD, gave the Maxwell Finland presentation she spoke of the continuing issues as well as the encouraging aspects that have institutions working on the problem.
A late-breaking IDWeek 2022 study found high seroprotection was achieved among people living with HIV after receiving 3 doses of a hepatitis B vaccine.
Amanda Jezek, senior vice president of public policy and government relations at IDSA, feels Congress is making significant progress toward antimicrobial resistance legislation.
During a late breaking session at ID Week, an investigator presented data on the GSK vaccine that is in development.
Advertisement
Related to this article
Charles M. Walworth, MD, of Labcorp discusses a new hepatitis D reflex pathway, internal data showing 8.3% of HBsAg-positive patients screened for HDV, and lessons from hepatitis C reflex testing.
David Altarac, MD, discusses 2025 SENTRY data, ESBL considerations in empiric therapy, and where ceftobiprole fits alongside ceftaroline in S aureus bacteremia.
Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Labcorp data presented at IDWeek 2026 show measles PCR testing nearly quadrupled and positivity rose sharply from April 2025 through March 2026, as clinicians shift toward guideline-recommended molecular testing amid ongoing US outbreaks.
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Advertisement
Advertisement
Trending on Contagion Live
1
Measles Update: November 6, 2026
2
Recent Guideline Updates in the Management of Urinary Tract Infections
3
Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions
4
Half of Long COVID Patients Substantially Improve Within 3 years
5